세계의 라이답(Rydapt) : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Rydapt was estimated to be worth US$ 335 million in 2024 and is forecast to a readjusted size of US$ 567 million by 2031 with a CAGR of 7.4% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Rydapt cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Rydapt is an oral small-molecule tyrosine kinase inhibitor primarily indicated for certain types of acute myeloid leukemia (AML) and systemic mastocytosis (SM). As a targeted therapy, Rydapt selectively inhibits signaling pathways associated with FLT3 gene mutations, thereby blocking the proliferation and survival of cancer cells. The drug has been approved by the U.S. FDA and the European EMA, becoming a standard treatment option for FLT3-positive AML patients. Often administered in combination with standard chemotherapy, Rydapt improves remission rates and overall survival, showing significant efficacy in both newly diagnosed and relapsed/refractory AML patients. The development and commercialization of Midostaurin represent a major advancement in precision medicine within hematologic oncology, greatly expanding targeted therapeutic options for AML.In 2024, global Rydapt production reached approximately 2.84 million unit, with an average global market price of around US$ 118/unit

With the widespread adoption of precision medicine and genetic testing technologies, detection rates of FLT3 gene mutations have significantly increased, expanding Rydapt's applicable patient population in AML. Corporate reports show that the global aging population and steady rise in AML incidence, particularly in developed countries, drive sustained demand for Rydapt. Multiple clinical studies confirm that Rydapt combined with standard chemotherapy substantially improves patient outcomes, earning guideline endorsements and enhancing market acceptance. Increased pharmaceutical investment in innovative targeted therapies promotes development of new indications and combination regimens, extending product lifecycle. Gradual inclusion in insurance coverage and streamlined market access reduce patient financial burden, expanding market penetration.

Despite promising prospects, Rydapt faces several challenges. High R&D and manufacturing costs lead to expensive treatment regimens, limiting accessibility in some regions. AML heterogeneity causes resistance to FLT3 inhibitors in certain patients, affecting sustained efficacy. Emerging competitors are launching more selective, potent next-generation FLT3 inhibitors, intensifying market competition. Additionally, underdeveloped healthcare reimbursement in emerging markets slows rapid adoption. Safety risk management and adverse event monitoring remain critical to ensure patient safety and regulatory compliance.

As molecular diagnostics mature, clinical demand for precise subtyping and personalized treatment is growing, driving Rydapt's use into early diagnosis and maintenance therapy. Pharmaceutical distribution channels and major hospitals steadily increase procurement of targeted therapies, especially in North America, Europe, and leading Chinese cities. Rising patient and physician acceptance of innovative therapies promotes market penetration. The rise of digital and remote healthcare platforms facilitates easier access to genetic testing and targeted medication, enhancing coverage. Strengthened collaborations between multinational pharma and local healthcare institutions support global commercial expansion of Rydapt.

This report aims to provide a comprehensive presentation of the global market for Rydapt, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Rydapt by region & country, by Type, and by Application.

The Rydapt market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rydapt.

Market Segmentation

By Company

• Novartis
• Glenmark Pharmaceuticals
• Zydus Cadila

Segment by Type

• AML
• ASM, SM-AHN, or MCL

Segment by Application

• Hospital
• Pharmacy

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Rydapt manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Rydapt in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Rydapt in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Rydapt Product Introduction
• 1.2 Global Rydapt Market Size Forecast
  • 1.2.1 Global Rydapt Sales Value (2020-2031)
  • 1.2.2 Global Rydapt Sales Volume (2020-2031)
  • 1.2.3 Global Rydapt Sales Price (2020-2031)
• 1.3 Rydapt Market Trends & Drivers
  • 1.3.1 Rydapt Industry Trends
  • 1.3.2 Rydapt Market Drivers & Opportunity
  • 1.3.3 Rydapt Market Challenges
  • 1.3.4 Rydapt Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Rydapt Players Revenue Ranking (2024)
• 2.2 Global Rydapt Revenue by Company (2020-2025)
• 2.3 Global Rydapt Players Sales Volume Ranking (2024)
• 2.4 Global Rydapt Sales Volume by Company Players (2020-2025)
• 2.5 Global Rydapt Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Rydapt Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Rydapt Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Rydapt
• 2.9 Rydapt Market Competitive Analysis
  • 2.9.1 Rydapt Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Rydapt Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rydapt as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 AML
  • 3.1.2 ASM, SM-AHN, or MCL
• 3.2 Global Rydapt Sales Value by Type
  • 3.2.1 Global Rydapt Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Rydapt Sales Value, by Type (2020-2031)
  • 3.2.3 Global Rydapt Sales Value, by Type (%) (2020-2031)
• 3.3 Global Rydapt Sales Volume by Type
  • 3.3.1 Global Rydapt Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Rydapt Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Rydapt Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Rydapt Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Hospital
  • 4.1.2 Pharmacy
• 4.2 Global Rydapt Sales Value by Application
  • 4.2.1 Global Rydapt Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Rydapt Sales Value, by Application (2020-2031)
  • 4.2.3 Global Rydapt Sales Value, by Application (%) (2020-2031)
• 4.3 Global Rydapt Sales Volume by Application
  • 4.3.1 Global Rydapt Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Rydapt Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Rydapt Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Rydapt Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Rydapt Sales Value by Region
  • 5.1.1 Global Rydapt Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Rydapt Sales Value by Region (2020-2025)
  • 5.1.3 Global Rydapt Sales Value by Region (2026-2031)
  • 5.1.4 Global Rydapt Sales Value by Region (%), (2020-2031)
• 5.2 Global Rydapt Sales Volume by Region
  • 5.2.1 Global Rydapt Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Rydapt Sales Volume by Region (2020-2025)
  • 5.2.3 Global Rydapt Sales Volume by Region (2026-2031)
  • 5.2.4 Global Rydapt Sales Volume by Region (%), (2020-2031)
• 5.3 Global Rydapt Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Rydapt Sales Value, 2020-2031
  • 5.4.2 North America Rydapt Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Rydapt Sales Value, 2020-2031
  • 5.5.2 Europe Rydapt Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Rydapt Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Rydapt Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Rydapt Sales Value, 2020-2031
  • 5.7.2 South America Rydapt Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Rydapt Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Rydapt Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Rydapt Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Rydapt Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Rydapt Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Rydapt Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Rydapt Sales Value, 2020-2031
  • 6.3.2 United States Rydapt Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Rydapt Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Rydapt Sales Value, 2020-2031
  • 6.4.2 Europe Rydapt Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Rydapt Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Rydapt Sales Value, 2020-2031
  • 6.5.2 China Rydapt Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Rydapt Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Rydapt Sales Value, 2020-2031
  • 6.6.2 Japan Rydapt Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Rydapt Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Rydapt Sales Value, 2020-2031
  • 6.7.2 South Korea Rydapt Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Rydapt Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Rydapt Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Rydapt Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Rydapt Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Rydapt Sales Value, 2020-2031
  • 6.9.2 India Rydapt Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Rydapt Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Novartis
  • 7.1.1 Novartis Company Information
  • 7.1.2 Novartis Introduction and Business Overview
  • 7.1.3 Novartis Rydapt Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Novartis Rydapt Product Offerings
  • 7.1.5 Novartis Recent Development
• 7.2 Glenmark Pharmaceuticals
  • 7.2.1 Glenmark Pharmaceuticals Company Information
  • 7.2.2 Glenmark Pharmaceuticals Introduction and Business Overview
  • 7.2.3 Glenmark Pharmaceuticals Rydapt Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Glenmark Pharmaceuticals Rydapt Product Offerings
  • 7.2.5 Glenmark Pharmaceuticals Recent Development
• 7.3 Zydus Cadila
  • 7.3.1 Zydus Cadila Company Information
  • 7.3.2 Zydus Cadila Introduction and Business Overview
  • 7.3.3 Zydus Cadila Rydapt Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Zydus Cadila Rydapt Product Offerings
  • 7.3.5 Zydus Cadila Recent Development

8 Industry Chain Analysis

• 8.1 Rydapt Industrial Chain
• 8.2 Rydapt Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Rydapt Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Rydapt Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer